An observational study in Lower Respiratory Tract Infection (LRTI), Chest Infection and Quality of Life, sponsored by University of Nottingham. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by University of Nottingham · Observational
Lower respiratory tract infections (LRTIs) are any infections below the vocal cords which affect the airways or the air sacs in the lungs. They include pneumonia, bronchitis and chest infections and are usually caused by viruses such as influenza, COVID-19 or Respiratory Syncytial Virus (RSV), or by bacteria such as pneumococcus. LRTIs are common, particularly in older adults; in the UK approximately 15% of people aged over 65 years will experience a chest infection each year and many of those will need in-patient treatment.
People who have had a chest infection may experience slow recovery after their infection. Patients often report that their quality of life is worse after an infection (for example persistent fatigue, reduced physical functioning, and mental health challenges) and this can affect the return to usual activities. However, there have not been many studies that have looked at how the quality of life changes in the months following a chest infection, and why some people take longer to recover.
In this study, the investigators will use a well-recognised questionnaire to measure quality of life for up to one year in adults who have been admitted to hospital with a chest infection. The findings will help the investigators to assess how long-term quality of life is affected after a chest infection and what factors may affect it. The results will also permit calculation of the costs faced by patients during recovery from a chest infection, in financial terms. These results will feed into studies looking at ways of improving recovery after a chest infection.
Acute lower respiratory tract infections (LRTIs) are a group of infections affecting the respiratory tract below the level of the larynx, including pneumonia, acute bronchitis, bronchiolitis, acute infective exacerbations of chronic obstructive pulmonary disease (COPD).
In those who survive their initial episode of LRTI, recovery may be slow with adverse outcomes which may last months or even years after the initial episode and have implications for patients, their families and health care resources. A recent prospective cohort study in the U.S. (PNEUMO) reported that at 6 months after hospitalisation with community-acquired pneumonia (CAP) and compared to their pre-hospitalisation status, 12.8% of participants had lost the ability to perform at least one basic activity of daily living (ADL), 22.0% lost the ability to perform at least one instrumental ADL, 41.6% suffered cognitive impairment, 58.7% had loss of employment, and 23.6% had decreased quality of life (Han et al 2025). Additionally pneumonia patients have high rates of readmission to hospital, which in turn is associated with significant inpatient mortality (Lawrence et al 2023), high rates of primary care consultation within 7 days of discharge (Baskaran et al 2021), increased risk of cardiovascular events and heart failure (Eurich et al 2017; Violi et al 2017), recurrent pneumonia (Baskaran et al 2022) and persistent symptoms (Pick et al 2019).
LRTIs therefore heavily impact patients, their families and carers, and the use of healthcare resources. Measuring the quality of life in patients hospitalised with acute LRTIs for up to one year after their discharge is an important component in the broader assessment of the cost of LRTIs in the UK, but long-term quality of life data in these patients are limited.
Every individual's experience of recovery from pneumonia is unique reflecting the complex interplay between their clinical characteristics, existing co-morbidities, frailty, physical and mental status, illness severity, and underlying causative micro-organism. There are few long-term data on outcomes which are important to patients following an episode of LRTI, including patient-perceived quality of life. It is therefore important to study this outcome and to identify those factors which may be associated with quality-of life measures in order to: a) gain a broader picture of the impact of LRTI on patients themselves; b) inform future trials assessing interventions aimed at improving patients' quality of life; c) to feed into analyses of the health economic costs of LRTIs.
The purpose of this study is to gain a better understanding of how health-related quality of life is affected in people who are hospitalised after a LRTI. The primary objective is to document health states and utility indexes for hospitalised LRTI patients and their evolution over the course of one year after the initial episode. The secondary objective is to evaluate associations between patient characteristics and their hospital stay with their health-related quality of life.
Participants will be recruited when they are almost ready to be sent home from hospital. Informed consent will be obtained prior to participation (or for those lacking capacity to provide consent, a consultee acting on their behalf will complete a declaration form). Before discharge participants will be asked to complete the EQ-5D-5L health-related quality of life questionnaire . After discharge from hospital, participants will complete the same questionnaire at one month, three months, six months and one year after discharge. Questionnaires will be administered by telephone, digitally (email form) or by post.
Descriptive statistics will be conducted at each time point (discharge, 1, 3, 6, 12 months):
Quality-Adjusted Life Years (QALYs) will be calculated using area-under-the-curve with trapezoidal rule and linear interpolation:
Formula: QALY per interval = [(Ustart + Uend) / 2] × time in years. Total QALYs =
Health state utility values reported by severity tier and time point will serve as inputs for cost-effectiveness models, where survival is incorporated through model structure using transition probabilities derived from the linked CPRD-HES cohort.
All cohorts will be stratified by age, sex, severity tier, diagnostic category, index of Multiple Deprivation quintile, number of co-morbidities, ECOG Performance Status, CURB-65 score.
To model utility trajectories over time and identify predictors of recovery, the investigators will use mixed-effects linear regression with random intercepts. Fixed effects: time, age, sex, severity tier, performance status, comorbidity count. Time × severity interaction explored to assess differential recovery rates. Predicted 12-month utilities derived from model.
Because EQ-5D utility values have an upper limit and many patients may report full health at follow-up, the investigators will check whether the model fits the data and produces realistic predicted values. If predictions fall outside the valid range or the model performs poorly, alternative approaches (such as Tobit regression, generalised linear models with clustered responses, or two-part models) will be explored in sensitivity analyses.
Missing data: Completion rates will be reported by timepoint and baseline characteristics compared between completers and non-completers. The following sensitivity analyses for missing data will be performed (a) multiple imputation by chained equations (MICE) conditional on baseline characteristics and severity tier, with last observation carried forward (LOCF) as conservative comparator; (b) Complete case: restricted to participants with EQ-5D-5L data at all five timepoints.
1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.
This study's planned enrollment of 200 is below the median of 252 across 535 observational studies indexed under Pneumonia.
Browse Pneumonia studies →University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited from the adult respiratory wards at Nottingham City Hospital as the majority of patients with a primary diagnosis of lower respiratory tract infection are admitted to these wards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults hospitalised with a lower respiratory tract infection (low, moderate or severe severity).
Change from baseline in health state utility values over one year
Health state utility values calculated from EQ-5D-5L profiles using preference-based value sets pre-discharge and at 1, 3, 6 and 12 months post-discharge.
Time frame: From enrolment to one year post-discharge from hospital
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.